Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Loss of hepatic Mboat7 leads to liver fibrosis
Veera Raghavan Thangapandi, Oskar Knittelfelder, Mario Brosch, et al.
Gut (2020) Vol. 70, Iss. 5, pp. 940-950
Open Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

Mechanisms and disease consequences of nonalcoholic fatty liver disease
Rohit Loomba, Scott L. Friedman, Gerald I. Shulman
Cell (2021) Vol. 184, Iss. 10, pp. 2537-2564
Open Access | Times Cited: 1228
Role of Insulin Resistance in MAFLD
Yoshitaka Sakurai, Naoto Kubota, Toshimasa Yamauchi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4156-4156
Open Access | Times Cited: 265
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Kalliopi Pafili, Michael Roden
Molecular Metabolism (2020) Vol. 50, pp. 101122-101122
Open Access | Times Cited: 239
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 146
Multiomics study of nonalcoholic fatty liver disease
Garðar Sveinbjörnsson, Magnús Ö. Úlfarsson, Rósa B. Þórólfsdóttir, et al.
Nature Genetics (2022) Vol. 54, Iss. 11, pp. 1652-1663
Open Access | Times Cited: 129
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei‐Chuan Lee, Pei-Shan Wu, Han‐Chieh Lin
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. 1, pp. 77-98
Open Access | Times Cited: 104
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Shuang Wang, Scott L. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 716
Open Access | Times Cited: 50
MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges
Anju Phoolchund, Salim I. Khakoo
Cancers (2024) Vol. 16, Iss. 2, pp. 259-259
Open Access | Times Cited: 26
Genetic and epigenetic factors determining NAFLD risk
Wenke Jonas, Annette Schürmann
Molecular Metabolism (2020) Vol. 50, pp. 101111-101111
Open Access | Times Cited: 117
Liver X Receptors: Regulators of Cholesterol Metabolism, Inflammation, Autoimmunity, and Cancer
Maria Teresa Bilotta, Sara Petillo, Angela Santoni, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 116
Recent advances in analytical strategies for mass spectrometry-based lipidomics
Tianrun Xu, Chunxiu Hu, Qiuhui Xuan, et al.
Analytica Chimica Acta (2020) Vol. 1137, pp. 156-169
Open Access | Times Cited: 108
MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
Yingxin Xian, Jianping Weng, Fen Xu
Chinese Medical Journal (2020) Vol. 134, Iss. 1, pp. 8-19
Open Access | Times Cited: 85
Update and nomenclature proposal for mammalian lysophospholipid acyltransferases, which create membrane phospholipid diversity
William J. Valentine, K. Yanagida, Hiroki Kawana, et al.
Journal of Biological Chemistry (2021) Vol. 298, Iss. 1, pp. 101470-101470
Open Access | Times Cited: 82
Nonalcoholic fatty liver disease stratification by liver lipidomics
Olga Vvedenskaya, Tim Rose, Oskar Knittelfelder, et al.
Journal of Lipid Research (2021) Vol. 62, pp. 100104-100104
Open Access | Times Cited: 57
Functionalizing multi-component bioink with platelet-rich plasma for customized in-situ bilayer bioprinting for wound healing
Ming Zhao, Jing Wang, Jinxin Zhang, et al.
Materials Today Bio (2022) Vol. 16, pp. 100334-100334
Open Access | Times Cited: 56
Dynamic human liver proteome atlas reveals functional insights into disease pathways
Lili Niu, Philipp E. Geyer, Rajat Gupta, et al.
Molecular Systems Biology (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 46
Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction
Amedeo Lonardo, Ashwani K. Singal, Natalia A. Osna, et al.
Metabolism and Target Organ Damage (2022) Vol. 2, pp. 12-12
Open Access | Times Cited: 41
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Leke Wiering, Pallavi Subramanian, Linda Hammerich
Cellular and Molecular Gastroenterology and Hepatology (2023) Vol. 15, Iss. 6, pp. 1277-1292
Open Access | Times Cited: 32
Lipid network and moiety analysis for revealing enzymatic dysregulation and mechanistic alterations from lipidomics data
Tim Rose, Nikolai Köhler, Lisa Falk, et al.
Briefings in Bioinformatics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 30
Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies
Xin Ding, Xu He, Bulang Tang, et al.
Chinese Medicine (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 9
Diabetes as a risk factor for MASH progression
Sofiya Gancheva, Michael Roden, Laurent Castéra
Diabetes Research and Clinical Practice (2024) Vol. 217, pp. 111846-111846
Open Access | Times Cited: 9
Genetic factors shaping the plasma lipidome and the relations to cardiometabolic risk in children and adolescents
Yun Huang, Sara Stinson, Malte Thodberg, et al.
EBioMedicine (2025) Vol. 112, pp. 105537-105537
Open Access | Times Cited: 1
Genetics Is of the Essence to Face NAFLD
Marica Meroni, Miriam Longo, Giada Tria, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1359-1359
Open Access | Times Cited: 50
Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets
Cristiana Bianco, Elia Casirati, Francesco Malvestiti, et al.
JHEP Reports (2021) Vol. 3, Iss. 3, pp. 100284-100284
Open Access | Times Cited: 43
Targeting cell-intrinsic metabolism for antifibrotic therapy
Hélène Gilgenkrantz, Ariane Mallat, Richard Moreau, et al.
Journal of Hepatology (2021) Vol. 74, Iss. 6, pp. 1442-1454
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top